| 12th Sep 2024 7:00 am |
RNS |
Positive mRNA flu vaccine Phase II headline data |
| 11th Sep 2024 5:27 pm |
RNS |
Statement: Zantac (ranitidine) litigation |
| 11th Sep 2024 3:30 pm |
RNS |
Change of Registered Office |
| 11th Sep 2024 7:00 am |
RNS |
Update on phase I/II therapeutic HSV vaccine trial |
| 9th Sep 2024 2:30 pm |
RNS |
Depemokimab late-breaking data presented at ERS |
| 6th Sep 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 6th Sep 2024 7:00 am |
RNS |
Positive Phase III results for Nucala in COPD |
| 2nd Sep 2024 3:00 pm |
RNS |
Total Voting Rights |
| 29th Aug 2024 7:00 am |
RNS |
EMA approval on Arexvy for 50-59 at risk |
| 28th Aug 2024 7:10 am |
RNS |
SENKU Designation for Bepirovirsen in Japan |
| 28th Aug 2024 7:05 am |
RNS |
Nucala approved in Japan for use in CRSwNP |
| 28th Aug 2024 7:00 am |
RNS |
Statement: Zantac (ranitidine) litigation |
| 21st Aug 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 20th Aug 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 20th Aug 2024 7:00 am |
RNS |
B7-H3 ADC US FDA Breakthrough Therapy Designation |
| 16th Aug 2024 7:00 am |
RNS |
Statement: Zantac (ranitidine) litigation |
| 12th Aug 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 6th Aug 2024 7:00 am |
RNS |
Statement: Zantac (ranitidine) litigation |
| 2nd Aug 2024 7:00 am |
RNS |
FDA Expands Jemperli Approval |
| 1st Aug 2024 3:00 pm |
RNS |
Total Voting Rights |
| 31st Jul 2024 7:00 am |
RNS |
2nd Quarter Results |
| 29th Jul 2024 8:18 am |
RNS |
Statement: Zantac (ranitidine) litigation |
| 29th Jul 2024 7:00 am |
RNS |
CHMP positive opinion on Arexvy for 50-59 at risk |
| 19th Jul 2024 10:36 am |
RNS |
Blenrep EMA Filing Acceptance |
| 18th Jul 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 16th Jul 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 15th Jul 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 12th Jul 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 3rd Jul 2024 7:00 am |
RNS |
GSK and CureVac collaboration restructured |
| 1st Jul 2024 3:00 pm |
RNS |
Total Voting Rights |
| 28th Jun 2024 5:37 pm |
RNS |
Statement: Zantac (ranitidine) litigation |
| 24th Jun 2024 7:05 am |
RNS |
Omjjara approved in Japan for myelofibrosis |
| 24th Jun 2024 7:00 am |
RNS |
EMA validates Jemperli marketing authorisation |
| 21st Jun 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 12th Jun 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 11th Jun 2024 7:00 am |
RNS |
Statement: Zantac (ranitidine) litigation |
| 10th Jun 2024 6:27 pm |
RNS |
Statement: Zantac (ranitidine) litigation |
| 10th Jun 2024 7:00 am |
RNS |
FDA approves Arexvy for adults 50-59 at risk |
| 3rd Jun 2024 3:00 pm |
RNS |
Total Voting Rights |
| 3rd Jun 2024 1:03 pm |
RNS |
Unprecedented results in Jemperli trial continue |
